Đang tải...

Early treatment with IgM-enriched intravenous immunoglobulin does not mitigate critical illness polyneuropathy and/or myopathy in patients with multiple organ failure and SIRS/sepsis: a prospective, randomized, placebo-controlled, double-blinded trial

INTRODUCTION: Critical illness polyneuropathy and/or myopathy (CIPNM) is a severe complication of critical illness. Retrospective data suggest that early application of IgM-enriched intravenous immunoglobulin (IVIG) may prevent or mitigate CIPNM. Therefore, the primary objective was to assess the ef...

Mô tả đầy đủ

Đã lưu trong:

Chi tiết về thư mục
Những tác giả chính:	Brunner, Richard, Rinner, Walter, Haberler, Christine, Kitzberger, Reinhard, Sycha, Thomas, Herkner, Harald, Warszawska, Joanna, Madl, Christian, Holzinger, Ulrike
Định dạng:	Artigo
Ngôn ngữ:	Inglês
Được phát hành:	BioMed Central 2013
Những chủ đề:	Research
Truy cập trực tuyến:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4056097/ https://ncbi.nlm.nih.gov/pubmed/24088271 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/cc13028
Các nhãn:	Thêm thẻ Không có thẻ, Là người đầu tiên thẻ bản ghi này!

Early treatment with IgM-enriched intravenous immunoglobulin does not mitigate critical illness polyneuropathy and/or myopathy in patients with multiple organ failure and SIRS/sepsis: a prospective, randomized, placebo-controlled, double-blinded trial

Những quyển sách tương tự